Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
LP Andrews, H Yano, DAA Vignali - Nature immunology, 2019 - nature.com
Although immunotherapeutics targeting the inhibitory receptors (IRs) CTLA-4, PD-1 or PD-
L1 have made substantial clinical progress in cancer, a considerable proportion of patients …
L1 have made substantial clinical progress in cancer, a considerable proportion of patients …
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.
LP Andrews, H Yano, DAA Vignali - Nature Immunology, 2019 - europepmc.org
Although immunotherapeutics targeting the inhibitory receptors (IRs) CTLA-4, PD-1 or PD-
L1 have made substantial clinical progress in cancer, a considerable proportion of patients …
L1 have made substantial clinical progress in cancer, a considerable proportion of patients …
[引用][C] Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
LP Andrews, H Yano, DAA Vignali - Nature Immunology, 2019 - cir.nii.ac.jp
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
LP Andrews, H Yano, DAA Vignali - Nature immunology, 2019 - pubmed.ncbi.nlm.nih.gov
Although immunotherapeutics targeting the inhibitory receptors (IRs) CTLA-4, PD-1 or PD-
L1 have made substantial clinical progress in cancer, a considerable proportion of patients …
L1 have made substantial clinical progress in cancer, a considerable proportion of patients …
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
LP Andrews, H Yano, DAA Vignali - paper.sciencenet.cn
Although immunotherapeutics targeting the inhibitory receptors (IRs) CTLA-4, PD-1 or PD-
L1 have made substantial clinical progress in cancer, a considerable proportion of patients …
L1 have made substantial clinical progress in cancer, a considerable proportion of patients …
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.
LP Andrews, H Yano, DAA Vignali - Nature Immunology, 2019 - go.gale.com
Although immunotherapeutics targeting the inhibitory receptors (IRs) CTLA-4, PD-1 or PD-
L1 have made substantial clinical progress in cancer, a considerable proportion of patients …
L1 have made substantial clinical progress in cancer, a considerable proportion of patients …